Equillium, Inc. (EQ) Stock Analysis & Investment Frameworks
Equillium, Inc. (EQ) stock analysis on Invetso. Review Equillium, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Equillium, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Equillium, Inc. Key Financial Metrics
- Market Cap: $77.99M
- Revenue: $N/A
- ROE: -41.15%
- ROIC: -34.10%
- Dividend Yield: N/A
About Equillium, Inc.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Equillium, Inc. Investment Frameworks
Invetso analyzes Equillium, Inc. (EQ) across the following frameworks:
- Equillium, Inc. 10Y Growth Potential
- Equillium, Inc. Scenario Analysis
- Equillium, Inc. Risks & Opportunities
- Equillium, Inc. Economic Moat
- Equillium, Inc. Business Model
- Equillium, Inc. Management
- Equillium, Inc. SWOT Analysis
- Equillium, Inc. Porter's 5 Forces
- Equillium, Inc. PESTLE Analysis
- Equillium, Inc. ESG Analysis